Study Spotlight

Study Spotlight

Coenzyme Q10 for Parkinson's Disease


In this Cochrane review, the authors analyzed results from randomized, double-blind, placebo-controlled trials involving a total of 452 patients, that compared the effects of coenzyme Q10 to placebo in patients suffering from early and mid-stage primary Parkinson's disease. Results found that coenzyme Q10 at a dose of 1200 mg/d for a period of 16 months was tolerated well by patients with Parkinson's disease and was associated with improvements in activities of daily living (WMD - 3.12) and Scwab and England (WMG 4.43) scores. Only mild elevations in risk ratios for diarrhea (RR=1.39) and pharyngitis (RR=1.04) were associated with coenzyme Q10 intake, but there were not differences in the coQ10 group versus the placebo group in terms of the number of patients who withdrew from the study due to adverse effects. The authors conclude, "Coenzyme Q10 therapy with 1200 mg/d for 16 months was well tolerated by patients with Parkinson's disease. The improvement s in ADL UPDRS and Schwab and England were positive, but it need to be further confirmed by larger sample."

Click Here to visit the journal website. Subscription required to view the full text of the article.

Socialize
Website by Webfitters